Biomarkers in Drug formulation

Drug formulation also covers the surrogate end points in the use of biomarkers and patient selection or companion diagnostics and provides insights into clinical biomarker discovery and biomarker development or validation with regulatory implications. Biomarker use can improve pharmaceutical development efficiency by helping to select patients most appropriate for treatment using a given mechanism, optimize dose selection, and provide earlier confidence in accelerating or discontinuing compounds in clinical development.

Biomarker in Drug discovery

 

Biomarker in Drug Design

 

Dose selection in Biomarker

 

Biomarkers of Toxicity & Pharmacology

 

Biomarkers in dose selection

 

Evaluation of dose respons

 

    Related Conference of Biomarkers in Drug formulation

    July 23-24, 2026

    37th European Heart and Heart Failure Congress

    Paris, France
    August 27-28, 2026

    22nd Global Biomarkers and Clinical Research Summit

    Paris, France
    September 14-15, 2026

    7th Global Summit on Digital Therapeutics

    Barcelona, Spain
    September 28-29, 2026

    13th International Conference on Stroke and Neurological Disorders

    Amsterdam, Netherlands
    October 19-20, 2026

    6th Euro-Global Summit on Probiotics & Nutraceuticals

    Paris, France
    November 16-17, 2026

    11th Global Summit on Midwifery and Womens Health

    Tokyo, Japan
    December 16-17, 2026

    7th Global Summit on Public Health

    Amsterdam, Netherlands
    January 18-19, 2027

    10th World Congress on PCOS and Reproductive Healthcare

    Bangkok, Thailand
    January 18-19, 2027

    44th International Conference on Women's Health

    Bangkok, Thailand
    February 01-02, 2027

    9th International Conference on Digital Health

    London, UK

    Biomarkers in Drug formulation Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in